PathogenDx Announces $7.five Million in Series B Funding

[ad_1]

TUCSON, Ariz. – PathogenDx, Inc., an innovator in DNA-primarily based pathogen testing technologies for the cannabis, hemp, agriculture and meals security industries, currently announced $7.five million in Series B funding. This most current investment round was led by Cresco Capital Partners with participation from Altitude Investment Management, Arcadian Investment Partners, Panther Chance Fund LLC, Salveo Capital, Flatiron Venture Partners and other investors. PathogenDx was in a position to close this round of funding in just beneath 3 months.

The added investment will enable PathogenDx to continue expanding its breakthrough technologies into meals and agriculture testing, even though continuing to construct on its leadership position with existing portfolio of domestic and international clientele in the cannabis sector. This news comes on the heels of PathogenDx’s announcement earlier this year concerning the broader application of their proprietary microarray technologies for fast strain identification that can reveal bacterial and fungal test final results in six hours or significantly less, compared to the sector regular of 72 hours or longer. PathogenDx anticipates complete federal approval of its technologies by initial half of 2020.

Advertisement

Polysciences SuperCool728x90

“PathogenDx has pioneered 1 of the most precise and cutting-edge pathogen testing
technologies on the market place. This investment is a crucial vote of self-confidence by sector leaders that our technologies can and will make a substantial effect across all pathogen testing industries,” stated CEO Milan Patel. “Our purpose for the subsequent year is to expand our DNA processing so other industries have access to economical and dependable pathogen test final results to strengthen solution security and safeguard customer well being.”

“PathogenDx is proving they have the break-by way of technologies and group to disrupt each testing and solution requirements all through the agricultural, meals and healthcare industries,” stated PathogenDx Board Member Ephraim Lindenbaum, Managing Director at Advance Ventures, a Silicon Valley primarily based AgTech, FoodTech and Digital Well being investor.

“We are consistently seeking for revolutionary companies to construct a robust cannabis market place, and we have been completely impressed by Milan Patel’s extended term vision for each his firm and the sector,” stated Matt Hawkins, Managing Companion at Cresco Capital Partners. “Patel and his group have the expertise and passion to build the subsequent regular-bearer in pathogen testing technologies, and we are thrilled to companion with them.”


ABOUT PATHOGENDX
Headquartered in Scottsdale, Arizona, PathogenDx’s mission is to develop into the new regular in DNA-primarily based testing by way of widespread adoption of its sophisticated microarray testing platform for the cannabis, hemp, agriculture, meals and beverage industries. PathogenDx’s technologies can quickly recognize and detect up to 50 pathogens all in a single test, in six hours offering triplicate information per analyte for certainty in final results with a basic and quick method. The company’s DNA-testing products–DetectX, QuantX, and EnviroX–are disrupting the century-old practice of petri-dish testing to recognize, detect and quantify pathogens like E. Coli, Salmonella and Aspergillus. This technologies will support increasing companies provide safer items and healthier lives, even though stopping millions of dollars in losses from contaminated or spoiled crops.

[ad_2]

Latest posts